MedTrace Logo

A Study of PY314 in Subjects With Advanced Solid Tumors

NCT04691375 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2024-03-22

No results posted yet for this study

Summary

This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including pembrolizumab, if approved for that indication).

Conditions

Interventions

DRUG

PY314

Dose of PY314 as a single agent given in a standard 3+3 design.

DRUG

Combination Therapy: PY314 + Pembrolizumab

Dose of PY314 alone and given in combination with pembrolizumab

Sponsors & Collaborators

  • Ikena Oncology

    lead INDUSTRY

Principal Investigators

  • Len Reyno, MD · Ikena Oncology

  • Marc Chamberlain, MD · Ikena Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2023-08-31
Completion
2023-09-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04691375 on ClinicalTrials.gov